Biopharmaceutical benchmarks 2014
Gary Walsh · Nature Biotechnology · 2014
Cited by 1,008 works. doi:10.1038/nbt.3040
Authors
References
- Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp
- Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques
- Biopharmaceutical benchmarks 2010
- Biopharmaceutical benchmarks 2006
- The economics of biosimilars.
- Antibody–drug conjugates: current status and future directions
- Approval of the first biosimilar antibodies in Europe
- The special case of gene therapy pricing
- Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells
- Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results Of The CLL11 Trial